Cidara and Mundipharma have a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of invasive fungal disease in all markets outside of the U.S. and Japan, which are retained by Cidara. Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain & Supportive Care and Consumer Healthcare as well as other severe and debilitating disease areas. Mundipharma submitted a marketing authorization application (MAA) for rezafungin to the European Medicines Agency (EMA) for the treatment of invasive candidiasis in adult patients. The MAA was accepted on August 22, 2022.